Professor Kim Eun-kyung's team from Daegu's Gyeongbuk Institute of Science and Technology discovers a substance for obesity treatment without side effects = South Korea

The Korea Research Foundation recently announced that a research team led by Professor Kim Eun-kyung of the Daegu Gyeongbuk Institute of Science and Technology (DGIST) has discovered a new substance, hexagon, that is a candidate for an obesity treatment drug.
announced that they have elucidated the mechanism by which sameethylene bisacetamide (HMBA) improves metabolism. In the development of obesity treatment drugs in the global pharmaceutical industry, appetite suppressants are the basis for therapeutic drugs.
development has become mainstream. However, these come with side effects such as anxiety, vomiting, and central nervous system disruption. Therefore, a therapeutic drug using glucagon-like peptide that lowers blood sugar and has a weight loss effect is developed.
being developed. However, this method requires injection using a syringe and has the disadvantage of being expensive. Professor Kim's research team has investigated appetite control in neurons in the arcuate nucleus of the hypothalamus.
We conducted research by modulating the expression of neuropeptides that promote appetite and neuropeptides that suppress appetite. When HMBA is administered intravenously to obese mice, it stimulates the nerve receptors that promote appetite.
While putido decreased, appetite-suppressing neuropeptides increased. HMBA-treated mice suppressed appetite, decreased body fat, activated brown fat cells that suppress food intake, and increased energy expenditure.
Effects such as weight loss and improvement in sugar metabolism were also confirmed. Professor Kim said, ``We were able to open up a new path to treating diseases such as obesity and diabetes.''